Aprepitant Effective in Preventing CINV in Children
In the first large pediatric study of adding aprepitant to standard prophylaxis for CINV, researchers have found aprepitant to be significantly more effective than a comparator placebo-added regimen in preventing this complication in children.
Treatment With Enobosarm May Prevent Cancer-Induced Muscle Wasting in NSCLC
Treatment with enobosarm demonstrated an increase in lean body mass compared with a decline in LBM observed with placebo for patients with NSCLC.
Palonosetron With Single-Dose of Dexamethasone Adequate for Controlling CINV
Palonosetron administered with a single-dose of dexamethasone adequately controlled nausea and vomiting associated with non-anthracycline-based (non-AC) moderately emetogenic chemotherapy (MEC).
NEPA Demonstrates Superiority Over Palonosetron Alone for CINV
NEPA, a treatment intended to control CINV that combines netupitant and palonosetron, demonstrated superior activity in complete response rates (from 0 to 120 hours) over oral palonosetron monotherapy.
2 Commerce Drive Cranbury, NJ 08512